Binds Virus Or Component Or Product Thereof (e.g., Virus-associated Antigen, Etc.) Patents (Class 530/389.4)
-
Publication number: 20130004496Abstract: Monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes or neuraminidase glycoprotein of N1 subtypes of avian influenza virus (AIV) are provided. The monoclonal antibodies and related binding proteins are useful for the detection of H5 and N1 subtypes of AIV, including H5N1 subtypes and provide means for the diagnosis, surveillance and treatment of dangerous viral infections.Type: ApplicationFiled: September 11, 2012Publication date: January 3, 2013Applicant: Temasek Life Sciences Laboratory LimitedInventors: Hong Liang Qian, Fang He, Hwei-Sing Kwang
-
Publication number: 20120321699Abstract: The present invention relates, in general, to an immunogen for HIV vaccination and, in particular, to a method of inducing the production of protective anti-HIV antibodies by targeting B cell germline and clone intermediates using a combination of HIV envelope and non-HIV immunogens. The invention also relates to compositions suitable for use in such a method.Type: ApplicationFiled: February 25, 2011Publication date: December 20, 2012Inventors: Barton F. Haynes, Hua-Xin Liao, Georgia Tomaras, Thomas B. Kepler, Kwan-Ki Hwang, S.Munir Alam, Yang Liu, T. Matt Holl, Guang Yang, Garnett Kelsoe, Mattia Bonsignori
-
Publication number: 20120308580Abstract: There is provided at least one isolated TCR-like antibody or fragment thereof, wherein the antibody or fragment thereof is capable of specifically binding to at least one HBV derived peptide.Type: ApplicationFiled: November 19, 2010Publication date: December 6, 2012Applicants: NATIONAL UNIVERSITY OF SINGAPORE, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Antonio Bertoletti, Sastry Konduru Seetharama, Paul Anthony Macary, Soh Ha Chan, Chien Tei Too
-
Publication number: 20120288510Abstract: Isolated human monoclonal antibodies which bind to hepatitis C virus (HCV), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: February 13, 2008Publication date: November 15, 2012Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Donna M. Ambrosino, William D. Thomas, JR., Gregory J. Babcock, Teresa Broering, Susan Sloan
-
Publication number: 20120282264Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.Type: ApplicationFiled: September 24, 2010Publication date: November 8, 2012Inventors: John R. Mascola, Richard Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary Nabel, Peter Kwong, Tongqing Zhou, Mark Connors, Gilad Ofek, Lawrence Shapiro, Jiang Zhu, William R. Schief
-
Publication number: 20120282273Abstract: Antibodies that bind with high affinity to swine H1N1 virus are described. In vivo experiments showed that one such antibody is able to fully protect mice challenged with a lethal dose of swine H1N1 virus. The antibody is also able to cure mice in a therapeutic setting when treated as late as up to 60 hours (2.5 days) after infection with swine H1N1 virus. Also described are recombinant forms of this antibody.Type: ApplicationFiled: October 12, 2010Publication date: November 8, 2012Inventors: Jens Wrammert, Rafi Ahmed, Patrick Wilson
-
Publication number: 20120276115Abstract: Described are binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. Also described are nucleic acid molecules encoding the antibodies, and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis, and/or treatment of an influenza virus H5N1 infection. In certain embodiments, the antibodies provide cross-subtype protection in vivo, such that infections with H5, H2, H6, H9, and H1-based influenza subtypes can be prevented and/or treated.Type: ApplicationFiled: April 27, 2012Publication date: November 1, 2012Inventors: Edward Norbert Van Den Brink, Cornelis Adriaan De Kruif, Mark Throsby
-
Publication number: 20120269821Abstract: The present invention relates, in general, to HIV-1 antibodies and, in particular, to broadly neutralizing HIV-1 antibodies that target the gp41 membrane-proximal external region (MPER).Type: ApplicationFiled: December 8, 2011Publication date: October 25, 2012Inventors: Barton F. Haynes, Hua-Xin Liao, M. Anthony Moody, Lynn Morris, Salim S. Abdool Karim
-
Publication number: 20120263751Abstract: Provided herein is a vaccine which is safe and effective against Nipah virus infection and a vector which is used in the manufacture of this vaccine and to provide a bivalent vaccine which exhibits an excellent preventive effect against measles virus and Nipah virus infection and which eliminates complexity at the time of inoculation. Also provided is a recombinant measles virus in which is inserted a gene which encodes a protein involved in preventing Nipah infection into the measles virus genome. The protein involved in preventing Nipah virus infection is preferably G protein or F protein which is a membrane protein. Also provided is a bivalent vaccine against measles and Nipah virus infection which contains the recombinant measles virus.Type: ApplicationFiled: November 20, 2009Publication date: October 18, 2012Applicant: ARIGEN PHARMACEUTICALS, INC.Inventors: Chieko Kai, Misako Yoneda
-
Publication number: 20120266261Abstract: Neuroinvasive and neurovirulent strain of the West Nile virus, named IS-98-ST1, nucleic acid molecules derived from its genome, proteins and peptides encoded by said nucleic acid molecules, and uses thereof.Type: ApplicationFiled: March 16, 2012Publication date: October 18, 2012Inventors: Philippe Despres, Vincent Deubel, Jean-Louis Guenet, Marie-Thérèse Drouet, Mertyn Malkinson, Caroline Banet, Marie-Pascale Frenkiel, Marie-Pierre Courageot, Fasséli Coulibaly, Adeline Catteau, Marie Flamand, Patrick Weber, Pierre-Emmanuel Ceccaldi
-
Publication number: 20120264921Abstract: Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.Type: ApplicationFiled: July 8, 2010Publication date: October 18, 2012Applicant: GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Kyung Hwan Ryoo, Dong Hyuck Seo, Jean Man Kim, Yong Nam Shin, Sunmi Koo, Jung-Ae Lim, Mijung Lee, Yeon Kyung Lee, Misun Seo
-
Publication number: 20120258111Abstract: Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif.Type: ApplicationFiled: January 25, 2012Publication date: October 11, 2012Applicants: ServicesInventors: Ralph A. Tripp, Les Jones, Larry J. Anderson
-
Publication number: 20120237922Abstract: The present disclosure provides methods for determining whether a subject is infected with lymphocytic choriomeningitis virus (LCMV). These methods include obtaining a sample from a subject with increased susceptibility to LCMV infection, contacting the sample with one or more compositions for detecting LCMV, and determining whether the one or more compositions for detecting LCMV is associated with a marker of LCMV from the sample, wherein detection of an association indicates that that the subject is infected with LCMV.Type: ApplicationFiled: January 6, 2012Publication date: September 20, 2012Inventors: Jana Tomaskova, Juraj Kopacek, Jaromir Pastorek, Silvia Pastorekova
-
Publication number: 20120237527Abstract: Nucleotide sequences and fragments which code for a human endogenous retrovirus which is infectious. “Fragments” according to the present invention relate also to specific fragments of the sequences inserted into the vector pCR4-Topo and deposited as MERV-env, MERV-gag, MERV-prt and MERV-pol as mentioned above. Additionally, methods of using such sequences, polypeptides encoded by such sequences, antibodies directs against such sequences, and methods and compositions relating to the same are all contemplated.Type: ApplicationFiled: April 19, 2012Publication date: September 20, 2012Applicant: Avir Green Hills Biotechnology Research Development Trade AGInventors: Klaus Wolff, Hubert Pehamberger, Andreas Grassauer, Thomas Muster
-
Publication number: 20120225083Abstract: The invention is directed to polypeptides and polypeptide fragments from HIV-1 envelope (Env) proteins following the characterization of Env structures from environments where HIV isolates expose conserved neutralization-sensitive Env structures. There is provided a polypeptide being all or a fragment of an HIV-1 envelope protein from a transmission strain of HIV-1, the polypeptide having neutralization sensitive epitopes that are accessible.Type: ApplicationFiled: September 16, 2009Publication date: September 6, 2012Applicants: THE UNIVERSITY OF MELBOURNE, THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH, NEWSOUTH INNOVATIONS PTY LIMITEDInventors: Damian Purcell, Robert Center, Sharmila Mohana Rama Reddy, Anthony Dominic Kelleher, David Albert Cooper, Paul Rene Gorry, Jasminka Sterjovski
-
Publication number: 20120226023Abstract: Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.Type: ApplicationFiled: March 1, 2012Publication date: September 6, 2012Applicant: THE TRUSTEES OF PRINCETON UNIVERSITYInventors: Thomas Shenk, Dai Wang
-
Publication number: 20120208987Abstract: The present invention relates to systems, devices, and methods for performing biological reactions. In particular, the present invention relates to the use of lipophilic, water immiscible, or hydrophobic barriers in sample separation, purification, modification, and analysis processes.Type: ApplicationFiled: March 15, 2012Publication date: August 16, 2012Applicant: NORTHWESTER UNIVERSITYInventors: DAVID M. KELSO, Kunal Sur, Zaheer Parpia
-
Publication number: 20120164169Abstract: The present invention relates to mutant Bovine Herpesvirus 4 genomes, mutant Bovine Herpesvirus 4 viruses, to mutant Bovine Herpesvirus 4 genomes and viruses carrying a heterologous DNA sequence, cells transfected with mutant Bovine Herpesvirus 4 genomes, cells infected with mutant Bovine Herpesvirus 4 viruses, vaccines and carrier vaccines comprising such mutant Bovine Herpesvirus 4 viruses, methods for the preparation of such mutant Bovine Herpesvirus 4 genomes and such mutant Bovine Herpesvirus 4 viruses and to diagnostic test kits.Type: ApplicationFiled: September 2, 2010Publication date: June 28, 2012Inventors: Muriel Michèle Chantal Thirion, Alain Francis Claude Vanderplasschen
-
Publication number: 20120165512Abstract: The present invention relates to the use of a fully human antigen binding fragment of an antibody for the manufacture of a medicament for the treatment or diagnosis of an ocular disease upon topical administration. The invention further relates to a pharmaceutical composition for ocular topical administration for treatment or diagnosis of an ocular disease comprising a fully human binding fragment of an antibody. In particular, the antibody neutralises HSV1 and HSV2.Type: ApplicationFiled: May 4, 2010Publication date: June 28, 2012Applicant: RIBOVAX BIOTECHNOLOGIES S.A.Inventors: Claire Abadie, Jean-Marc Combette, Catherine Deloche, Robert Anthony Williamson
-
Publication number: 20120164155Abstract: The invention relates to chimeric proteins comprising an antigen and a trimer forming portion or a trimer and virus-like particle forming portion of foamy virus envelope protein (FV TM). The trimer or trimer and virus-like particle forming portion comprises i) full length foamy virus transmembrane protein; ii) foamy virus transmembrane protein absent a functional cytoplasmic domain; iii) foamy virus transmembrane protein absent a functional cytoplasmic domain and transmembrane domain; iv) foamy virus ectodomain comprising N-terminal heptad repeat region and cysteine rich region between N-terminal heptad repeat region and C-terminal ?-helical region; v) N-terminal heptad repeat region; vi) a functional variant of any one of i) to v); or vii) any one of i) to vi) lacking an FV fusion peptide domain. In particular, the antigen is an antigen of a virus envelope protein, such as HIV gp 120.Type: ApplicationFiled: June 22, 2010Publication date: June 28, 2012Applicant: The Macfarlane Burnet Institute for Medical Research and Public Health Ltd.Inventor: Elizabeth Grgacic
-
Publication number: 20120164659Abstract: The present invention generally relates to a method for identifying and cloning nucleic acid molecules encoding a new class of proteins or fragments thereof, capable of interacting with proteins associated with the Human Hepatitis C virus (HCV) and thus being suitable either alone or in complex with the HCV protein for serving as a target for the development of antiviral drugs. In this context, the present invention provides novel HCV-interacting proteins and complexes as well as antibodies which specifically recognize and bind to the complex or to specific domains of HCV proteins.Type: ApplicationFiled: August 4, 2010Publication date: June 28, 2012Applicant: NEXIGEN GMBHInventors: Claudia Carl, Hanjo Hennemann
-
Publication number: 20120164170Abstract: The invention relates to a novel porcine circovirus type 2 (PCV2) strain. The invention also relates to immunogenic compositions containing the novel PCV2 strain, PCV2 test kits, and applications of the novel PCV2 strain.Type: ApplicationFiled: December 20, 2011Publication date: June 28, 2012Inventors: Tsun-Yung KUO, Hsu Chung Gabriel Chen, Chung-Chin Wu, Han-Ting Chen
-
Publication number: 20120156242Abstract: Antigenic peptides are provided that can be used to induce global neutralizing antibodies, or antibodies reactive against a wide range of influenza A virus strains. The antigenic peptide can correspond to SEQ ID NO: 34 (EKEVLVLWG), SEQ ID NO: 2 (KFDKLYIWG), SEQ ID NO: 71(QEDLLVLWG), SEQ ID NO: 51 (EGRINYYWTLLEP), SEQ ID NO: 3 (PSRISIYWTIVKP), and/or SEQ ID NO: 82 (SGRMEFFWTILKP).Type: ApplicationFiled: June 16, 2010Publication date: June 21, 2012Inventors: Kazuyoshi Ikuta, Ritsuko Koketsu, Akifumi Yamashita, Norihito Kawashita, Mikihiro Yunoki, Yoshinobu Okuno, Shoji Ideno, Motoki Kuhara
-
Publication number: 20120141503Abstract: The present invention related to heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, suitable for use in the management of infections, in particular gastrointestinal tract. The present invention also relates to a delivery system comprising these heavy chain immunoglobulins or functional fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, and hosts comprising expression vectors encoding for these heavy chain immunoglobulins or functional fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof. The invention also related to food products and pharmaceutical preparations comprising the delivery system, and method for the preparation of food products according to the invention.Type: ApplicationFiled: January 23, 2012Publication date: June 7, 2012Inventors: Leo Gerardus Joseph Frenken, Lars-Göran Lennart Hammarström, Adrianus Marinus Ledeboer
-
Publication number: 20120141527Abstract: The invention provides structurally constrained viral peptides for use as therapeutic and vaccination agents, and for the production of antibodies for use in a number of applications including as therapeutic agents. The invention further provides methods and kits for use of the structurally constrained peptides and antibodies of the instant invention. The invention is based, at least in part, on the result provided herein demonstrating that viral hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.Type: ApplicationFiled: June 18, 2010Publication date: June 7, 2012Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Loren D. Walensky, Gregory Bird
-
Publication number: 20120135006Abstract: Ultra high affinity antibodies with binding affinities in the range of 1010 M?1, and even 1011 M?1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.Type: ApplicationFiled: October 24, 2011Publication date: May 31, 2012Applicant: MedImmune, LLCInventors: James F. Young, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Publication number: 20120128691Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: ApplicationFiled: December 28, 2011Publication date: May 24, 2012Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
-
Publication number: 20120128671Abstract: The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, and methods and means for making such antibodies.Type: ApplicationFiled: May 12, 2010Publication date: May 24, 2012Inventors: Lawrence Horowitz, Ramesh Bhatt, Arun Kashyap
-
Publication number: 20120128692Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: ApplicationFiled: December 28, 2011Publication date: May 24, 2012Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
-
Publication number: 20120128684Abstract: Disclosed are antibodies that bind to the stem region of influenza hemagglutinin in the neutral pH conformation, hemagglutinin epitopes in the stem region, and methods of making and using both.Type: ApplicationFiled: August 25, 2009Publication date: May 24, 2012Applicants: Burnham Institute for Medical Research, Dana-Farber Cancer Institute, Inc.Inventors: Wayne Marasco, Jianhua Sui, Robert C. Liddington
-
Publication number: 20120121633Abstract: Provided are immunogenic compositions based on the highly conserved, core CD4 binding site of the gp120 protein of the human immunodeficiency virus. One embodiment includes an antigenic conjugate of an electophilic derivative of HIV gp120 peptide 416-433, designated E-416-433, covalently linked to an immunogenic carrier protein. The compositions are effective in stimulating the production of HIV neutralizing antibodies in mammals. Provided also are related methods of immunization, methods of antibody production and antibodies obtained using the methods of the invention.Type: ApplicationFiled: July 16, 2011Publication date: May 17, 2012Inventors: Sudhir Paul, Yasuhiro Nishiyama, Stephanie Planoue, Richard J. Massey
-
Publication number: 20120121603Abstract: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.Type: ApplicationFiled: May 20, 2010Publication date: May 17, 2012Applicant: Theraclone Sciences, Inc.Inventors: Andres G. Grandea, III, Gordon King, Thomas c. Cox, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Phil Hammond
-
Publication number: 20120114664Abstract: Provided are human antibodies that can neutralize a H5N1 strain of influenza A virus. Also provided are antibodies that can neutralize a strain of influenza A virus in clade 2 of the H5 subtype, that can neutralize a H5N1 strain of influenza A virus and have a lambda light chain, and that are IgG antibodies (but not with a IgG1 heavy chain) that can neutralize a H5N1 strain of influenza A virus.Type: ApplicationFiled: January 16, 2012Publication date: May 10, 2012Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventor: Antonio Lanzavecchia
-
Publication number: 20120107357Abstract: Presented herein is the discovery of a new human picornavirus, Cosavirus (previously termed Dekavirus), methods of detecting the Cosavirus and diagnosing Cosavirus infection, methods of treating or preventing Cosavirus infection, and methods for identifying anti-Cosavirus compounds.Type: ApplicationFiled: March 19, 2009Publication date: May 3, 2012Applicant: Blood Systems, Inc.Inventors: Eric Delwart, Amit Kapoor, Joseph Victoria
-
Publication number: 20120090043Abstract: The invention concerns an isolated complex comprising an HIV or HTLV protein and a human protein. Corresponding nucleic acids, vectors, host cells, host organisms, compositions, kits, medical uses, diagnostic uses, and methods of screening agents are also contemplated. Disclosed are 212 interactions between 19 retroviral proteins and 131 human proteins.Type: ApplicationFiled: June 30, 2010Publication date: April 12, 2012Applicant: UNIVERSITE DE LIEGEInventors: Jean-Claude Twizere, Nicolas Simonis
-
Publication number: 20120088718Abstract: The present invention relates to Hepatitis C virus (HCV)-derived polypeptides and nucleic acid molecules encoding same which advantageously comprises a cd81-binding region. In this connection, the present invention specifically relates to the use of the polypeptides or nucleic acid molecules in compositions and methods for the prevention, the treatment and the diagnosis of HCV infections.Type: ApplicationFiled: March 17, 2010Publication date: April 12, 2012Applicant: INSTITUT PASTEURInventors: Thomas Krey, Felix A. Rey, Carlos Massayuki Kikuti, Laurence Damier-Piolle
-
Patent number: 8153129Abstract: The present invention provides novel antibody sequences that bind human cytomegalovirus (hCMV) and neutralize hCMV infection. The novel sequences can be used for the medical management of hCMV infections, in particular for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of hCMV infections.Type: GrantFiled: December 17, 2007Date of Patent: April 10, 2012Assignee: Ribovax Biotechnologies S.A.Inventors: Ada Funaro, Giorgio Gribaudo, Santo Landolfo
-
Publication number: 20120082666Abstract: The invention provides compositions comprising anti-gH antibodies and anti-Complex I antibodies as well as methods of using the same.Type: ApplicationFiled: September 29, 2011Publication date: April 5, 2012Inventors: Xiaocheng Chen, Mark Dennis, Becket Feierbach, Ashley Fouts, Isidro Hotzel, Bing Li
-
Publication number: 20120076801Abstract: The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.Type: ApplicationFiled: April 15, 2011Publication date: March 29, 2012Applicant: Humabs, LLCInventors: Antonio Lanzavecchia, Annalisa Macagno
-
Publication number: 20120076802Abstract: The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease.Type: ApplicationFiled: April 22, 2011Publication date: March 29, 2012Applicant: Humabs, LLCInventors: Antonio Lanzavecchia, Annalisa Macagno
-
Publication number: 20120070447Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: ApplicationFiled: October 18, 2010Publication date: March 22, 2012Applicant: MEDIMMUNE, LLCInventors: JAMES F. YOUNG, SCOTT KOENIG, LESLIE S. JOHNSON, WILLIAM D. HUSE, JEFFREY D. WATKINS, HERREN WU
-
Publication number: 20120070446Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.Type: ApplicationFiled: October 5, 2010Publication date: March 22, 2012Applicant: AIMM THERAPEUTICS B.V.Inventors: TIM BEAUMONT, ADRIANUS Q. BAKKER, ETSUKO YASUDA
-
Publication number: 20120064000Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: August 1, 2011Publication date: March 15, 2012Applicants: Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the United Sates of America, as represented by the Secretary, Department of HealthInventors: Dimiter S. Dimitrov, Zhongyu Zhu, Christopher C. Broder
-
Publication number: 20120058124Abstract: Provided is an anti-influenza virus antibody that exhibits neutralizing activity beyond the barrier of the two groups of influenza viruses categorized according to the conservativeness of hemagglutinin amino acids, a method of producing the same, and a test method for determining whether the subject carries the neutralizing antibody.Type: ApplicationFiled: August 4, 2011Publication date: March 8, 2012Applicants: The Research Foundation for Microbial Diseases of Osaka University, FUJITA HEALTH UNIVERSITYInventors: Yoshikazu KUROSAWA, Yoshitaka IBA, Nobuko OHSHIMA, Yoshinobu OKUNO
-
Publication number: 20120039846Abstract: The present invention provides identification and characterization of conformational epitopes of the envelope protein E2 of the Hepatitis C virus (HCV). The present invention provides a panel of human monoclonal antibodies that recognize conformational epitopes of E2. The antibodies are derived from patients infected with HCV. The present invention provides methods for utilizing HCV antibodies as therapeutic, diagnostic, and/or prophylactic agents. The present invention provides mimotopes with conformational epitopes intact and methods of using mimotopes. The present invention provides methods of stratifying patients based on their response to HCV. The present invention provides pharmaceutical compositions for prevention and treatment of HCV comprising one or more HCV antibodies.Type: ApplicationFiled: October 5, 2008Publication date: February 16, 2012Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Steven Foung, Zhen-yong Keck
-
Publication number: 20120039898Abstract: Binding molecules, such as human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, such as H3N2, and have a broad neutralizing activity against such influenza virus. Provided are nucleic acid molecules encoding the antibodies, their sequences and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis and/or treatment of an influenza virus H3N2 infection. The antibodies may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated.Type: ApplicationFiled: May 6, 2010Publication date: February 16, 2012Inventors: Mark Throsby, Robert Heinz Edward Friesen, Theodorus Hendrikus Jacobus Kwaks, Mandy Antonia Catharina Jongeneelen
-
Publication number: 20120039923Abstract: The present invention relates to modified HIV-1 envelope proteins where one or more N-glycosylation sites have been deleted or modified, which produce a broadly cross reactive neutralizing response, their methods of use and antibodies which bind to these proteins. The invention also provides for nucleic acids, vectors, antibodies and pharmaceutical compositions that comprise said modified HIV-1 envelope proteins.Type: ApplicationFiled: September 9, 2005Publication date: February 16, 2012Applicant: THE HENRY M. JACKSON FOUNDATIONInventors: Christopher Broder, Gerald Quinnan
-
Publication number: 20120039899Abstract: The present invention provides novel human anti-Influenza antibodies and related compositions and methods. These antibodies are used in the prevention, inhibition, neutralization, diagnosis, and treatment of influenza infection.Type: ApplicationFiled: August 12, 2011Publication date: February 16, 2012Applicant: THERACLONE SCIENCES, INC.Inventors: OLE OLSEN, CHRISTINA L. BOOZER, ANDRES G. GRANDEA, III
-
Publication number: 20120027777Abstract: The present invention relates to a Ljungan virus with improved replication characteristic and the use of this Ljungan virus, amongst other thing, in the production of a vaccine.Type: ApplicationFiled: January 22, 2010Publication date: February 2, 2012Applicant: APODEMUS ABInventors: Michael Lindberg, Conny Tolf
-
Publication number: 20120027776Abstract: An isolated nucleic acid molecule is disclosed, including a nucleotide sequence selected from the nucleotide sequence of (a) Ljungan virus 87-012, (b) Ljungan virus 145SL, (c) Ljungan virus 174F, and (d) a fragment of nucleotide sequences (a)-(c). Also disclosed are polypeptides encoded by the isolated nucleic acid, which are useful in preparing vaccines and antibodies to prevent or inhibit conditions caused by Ljungan virus, including diabetes.Type: ApplicationFiled: June 1, 2009Publication date: February 2, 2012Inventors: Bo Niklasson, Ake Lernmark